Allucent
- Company typePrivate
- Founded1993
- HeadquartersCary, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
Allucent firmographics
Firmographics- Name
- Allucent
- Legal name
- Allucent
- Website
- https://allucent.com
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Allucent industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where Allucent is headquartered
LocationHeadquarters
- HQ city
- Cary
- HQ country
- United States
- HQ region
- North America
Offices27 records
Markets served
Allucent business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- CRO Clinical Development Services: Allucent generates revenue as a full-service CRO providing comprehensive clinical development services to small and mid-sized biopharma companies. Revenue is derived from service contracts spanning study design, clinical operations, data management, biostatistics, regulatory strategy, pharmacovigilance, and post-marketing surveillance across all trial phases. The model is project-based and service-contract driven, with engagements ranging from standalone functional support to full-service integrated CRO partnerships. The company has supported 105+ successful marketing applications and 50+ approved and marketed products.
- Regulatory Strategy & Submissions: Regulatory strategy consulting and submissions services, including IND/NDA/BLA preparation, eCTD publishing, CMC and preclinical regulatory support, and GxP consulting. Revenue is generated through project-based consulting engagements and regulatory submission service contracts, supported by a team of 12 former regulators from 6 regulatory agencies.
- Clinical Pharmacology & Modeling Services: Specialized clinical pharmacology services including pharmacokinetics, pharmacodynamics, modeling and simulation, translational DMPK, and embedded clinical pharmacologist consulting. Supports 650+ drugs across all modalities, routes of administration, and therapeutic areas, with 6,650+ PK/PD/TK/QTc translational analyses conducted. Revenue from project-based and retainer consulting engagements.
- Drug Safety & Pharmacovigilance Services: Post-marketing and clinical trial drug safety and pharmacovigilance services including PV system setup, aggregate safety reports, risk management, global QPPV services, and expedited adverse event reporting. Revenue from ongoing service contracts with biopharma sponsors across clinical and post-marketing lifecycle stages.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Full-service CRO engagement model covering all clinical development phases |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels9 records
Allucent product offering
Product offeringCore offering
Allucent is a full-service Contract Research Organization (CRO) providing integrated clinical development services to small and mid-sized biopharma companies. The company offers end-to-end capabilities across clinical trial operations, clinical pharmacology and modeling & simulation, regulatory strategy and submissions, drug safety and pharmacovigilance, clinical data management, biostatistics, and medical monitoring, delivered through a proprietary IGNITE site network of 193 prequalified sites across 12 countries. Engagements span from preclinical through post-marketing surveillance under flexible full-service or standalone functional outsourcing models.
Product overview
Allucent is a global, full-service Contract Research Organization (CRO) offering an integrated platform of clinical development services for small and mid-sized biopharma companies. The portfolio centers on five core service pillars: Clinical Development Services (encompassing study start-up, patient recruitment, decentralized trials, data management, biostatistics, and medical monitoring), Clinical Pharmacology (including pharmacokinetics, modeling & simulation, and translational DMPK), Regulatory Strategy (spanning submissions, GxP consulting, and clinical/CMC strategy), Drug Safety & Pharmacovigilance (covering clinical trial safety and post-marketing surveillance), and the IGNITE Site Network (a global network of 193+ prequalified research sites). Supporting these core services are specialized modules including Patient Direct Trials (decentralized trial technology), Clinical Data Management, Biostatistics & Statistical Programming, Medical Monitoring, Patient Recruitment & Retention, Regulatory Submissions (using LORENZ docuBridge), Biostatistical Consulting, and Embedded Clinical Pharmacologist services. The platform is delivered through Allucent's Centers of Expertise (ACEs) structure focused on oncology, neuroscience, cardiometabolic, immunology, rare diseases, and advanced therapies.
Differentiator
Problem solved
Functional benefit
Brands
- IGNITE Site Network: Allucent's Integrated Global Network for Innovative Trial Execution (IGNITE™) is a global network of prequalified clinical research sites therapeutically aligned to the Allucent Centers of Expertise (ACE), designed to increase study predictability including study start-up, patient enrollment and overall study execution.
Products and services
- Clinical Development Services Comprehensive clinical trial operations including study start-up, patient recruitment, decentralized trials, data management, biostatistics, and medical monitoring for early- and late-phase programs. Designed for small and mid-sized biotech and biopharma sponsors needing end-to-end operational support.
- Clinical Pharmacology Services Drug development insights through pharmacokinetics, pharmacodynamics, modeling and simulation, translational DMPK, and clinical pharmacology study design including First-in-Human, SAD/MAD, and bioequivalence studies. Supports 650+ drugs across all modalities, routes of administration, and therapeutic areas.
- Regulatory Strategy Services Regulatory and drug development consulting including submissions strategy, compliance planning, expedited pathway designations, orphan drug strategy, pediatric development plans, eCTD publishing, GxP consulting, CMC and preclinical support, and biostatistical consulting. Supports IND, NDA, BLA, IDE, and IMPD submissions to FDA, EMA, Health Canada, and MHRA.
- Drug Safety & Pharmacovigilance Services Patient safety solutions spanning clinical trial safety, post-marketing surveillance, risk management, global QPPV services, and PV system setup and maintenance for biopharma sponsors across clinical and post-marketing lifecycle stages.
- IGNITE Site Network Global network of prequalified clinical research sites with 193 sites across 12 countries and a 40M+ patient pool. Therapeutically aligned to Allucent Centers of Expertise (ACEs) to accelerate study start-up, improve enrollment predictability, and deliver consistent trial execution from first patient in (FPI) through last patient in (LPI).
- Government & Public Health Services CRO services tailored for government-sponsored clinical research with partners including BARDA, U.S. Department of Defense, NINDS, and NIAID. Brings collective expertise to navigate unique regulatory and compliance requirements of public health programs, including FDA Animal Rule applications.
- Patient Direct Trials (Decentralized Clinical Trials) Decentralized clinical trial solution featuring eCOA, telehealth, site data capture, sensors & wearables, eConsent, patient notifications, home health, and IMP delivery, with real-time data visualization for sites. Designed for hybrid and fully decentralized study designs.
Quantifiable outcome
- 105+ successful marketing applications supported
- +4 more outcomes
Companies that use Allucent
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles2 records
Allucent technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Allucent partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor and core.
- XtalksminorXtalks hosts educational webinars featuring Allucent experts on clinical development topics including participant-site readiness for rare disease trials, AI and emerging technologies in clinical trials, pediatric rare disease trials, and navigating the Animal Rule. Xtalks serves as official Media Partner for the Toronto Life Sciences and Biotech Summit where Allucent presents.
- XtalksminorXtalks partnered with Allucent for a webinar on AI and emerging technologies in clinical trials, part of Xtalks' role as official Media Partner for the Toronto Life Sciences and Biotech Summit. Allucent experts discuss practical AI applications across protocol development, patient recruitment, trial operations, and regulatory considerations for decentralized trial models.
- BARDA (Biomedical Advanced Research and Development Authority)coreAllucent maintains specialized capabilities for government-sponsored and public health research, partnering with leading agencies including BARDA, Department of Defense, NINDS, and NIAID. The government services A-Team brings collective expertise to navigate unique regulatory and compliance requirements of government-sponsored clinical research programs.
- NINDS (National Institute of Neurological Disorders and Stroke)coreAllucent partners with NINDS for government-sponsored clinical research programs in neuroscience, navigating the unique regulatory and compliance requirements of NIH-sponsored drug development.
- NIAID (National Institute of Allergy and Infectious Diseases)coreAllucent partners with NIAID for government-sponsored clinical research programs in infectious diseases and vaccines, leveraging the institute's public health research mandate and Allucent's operational execution capabilities.
- U.S. Department of DefensecoreAllucent partners with the U.S. Department of Defense for government-sponsored clinical research, navigating unique regulatory and compliance requirements for defense-related public health programs.
- Quantum BioPharma Ltd.coreAllucent serves as the contract research organization managing the Phase 2 clinical trial for Lucid-MS, Quantum BioPharma's first-in-class neuroprotective drug candidate for multiple sclerosis. Allucent manages site selection, patient recruitment, and data analysis for the study. The trial was expected to begin in Q2 2026 pending regulatory approvals. A binding Letter of Intent was signed in March 2026.
- Massachusetts General HospitalcoreMassachusetts General Hospital scientists collaborate with Allucent on Phase 2 trials and validation of a novel PET imaging tracer for monitoring myelin integrity in the Lucid-MS multiple sclerosis program for Quantum BioPharma. The collaboration supports development of a PET imaging technique capable of directly measuring myelin integrity, addressing a critical challenge in remyelinating therapies.
- Queens University BelfastminorQueens University Belfast collaborated with Allucent on a webinar focused on transforming pediatric rare disease trials through model-informed drug development and specialized site networks. The partnership featured experts from both organizations discussing population pharmacokinetic modeling and clinical trial simulation approaches.
- Silo PharmacoreAllucent was selected to support the preparation and planned submission of an Investigational New Drug application to the FDA for SPC-15, an intranasal prophylactic treatment for PTSD. Services include GLP toxicology and drug-device study data coordination, with Phase 1 clinical trials planned following FDA IND approval. A non-binding Letter of Intent was established.
Scale indicators13 records
Recent moves6 records
Expansion highlights6 records
Allucent competitors and assessment
Company assessmentDirect peers
- Medpace: Medpace is a mid-to-large clinical CRO focused on small and mid-sized biopharma sponsors — directly comparable to Allucent's go-to-market model. Both compete on therapeutic depth and a high-touch, full-service operating model rather than scale-only differentiation, making Medpace the closest publicly traded comp.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a privately held, mid-sized full-service CRO with a strong focus on small and mid-sized biopharma sponsors across complex therapeutic areas. Its specialty positioning, mid-size scale, and biotech-centric GTM closely mirror Allucent's profile.
- Premier Research: Premier Research is a specialty CRO focused on small and mid-sized biopharma and rare disease/oncology programs. Its therapeutic specialization, mid-size footprint, and biotech sponsor focus make it a closely comparable niche CRO peer.
Emerging players
- Rho: Rho is a privately held, mid-sized CRO with strong focus on small and mid-sized biopharma sponsors, particularly in rare disease and immunology. It is a smaller, more focused peer with comparable biotech sponsor specialization.
Broad incumbents
- Charles River Laboratories: Charles River provides preclinical and clinical services with strong biotech sponsor coverage in early-phase and discovery work. Its preclinical-clinical integration and biotech focus make it a partial competitor in the same sponsor segment.
- Parexel International: Parexel is a large global CRO with strong biotech and small/mid-sponsor focus, particularly in oncology and rare disease. Its biotech-focused operating model and global site footprint compete with Allucent for the same sponsor segment.
- IQVIA: IQVIA is the largest global CRO with broad biotech, pharma, and post-approval service capabilities. It is a competitive incumbent across Allucent's therapeutic areas but operates at materially larger scale with broader portfolio breadth.
- Syneos Health: Syneos Health is a large CRO with combined clinical and commercial services, serving biotech and pharma sponsors across all trial phases. It competes with Allucent in clinical development and increasingly in decentralized trial delivery.
- ICON plc: ICON is a top-3 global CRO with full-service clinical development and significant biotech sponsor coverage. Following its PRA Health Sciences acquisition, ICON has expanded its biotech and specialty franchise and competes broadly with Allucent in clinical operations.
- Labcorp Drug Development (formerly Covance): Labcorp Drug Development is a top global CRO with integrated central laboratory and clinical development services. It competes broadly across Allucent's therapeutic areas and offers end-to-end biotech sponsor programs.
Market position
Strengths5 records
Weaknesses2 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Allucent social profiles
Digital presenceAllucent compliance and trust
Trust signalCompliance2 records
Allucent financial estimates
Financial estimateRevenue estimate
Valuation estimate
Allucent leadership team
Management profileNumber of profiles
Profiles28 records
Allucent funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Allucent M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Allucent
What does Allucent do?
Allucent is a full-service Contract Research Organization (CRO) providing integrated clinical development services to small and mid-sized biopharma companies. The company offers end-to-end capabilities across clinical trial operations, clinical pharmacology and modeling & simulation, regulatory strategy and submissions, drug safety and pharmacovigilance, clinical data management, biostatistics, and medical monitoring, delivered through a proprietary IGNITE site network of 193 prequalified sites across 12 countries. Engagements span from preclinical through post-marketing surveillance under flexible full-service or standalone functional outsourcing models.
Is Allucent a public or private company?
Allucent is a private company. It is classified as unknown and is currently operating.
When was Allucent founded?
Allucent was founded in 1993. It employs 1,001 to 5,000 people.
Where is Allucent based?
Allucent is headquartered in Cary, United States, in the North America region.
How does Allucent make money?
Four revenue lines are on record. CRO Clinical Development Services are the primary driver. The others are regulatory Strategy & Submissions, clinical Pharmacology & Modeling Services and drug Safety & Pharmacovigilance Services.
Who are Allucent's main competitors?
Direct peers on record are Medpace, Worldwide Clinical Trials and Premier Research. Rho is listed as an emerging player. Broad incumbents are Charles River Laboratories, Parexel International, IQVIA, Syneos Health, ICON plc and Labcorp Drug Development (formerly Covance).
Does Allucent have an API?
No public API is recorded for Allucent.
What industry is Allucent in?
Allucent's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.